LPL Antibody

中文名稱：

LPL兔多克隆抗體
貨號(hào)：

CSB-PA013065LA01HU
規(guī)格：

￥440
圖片：
IHC image of CSB-PA013065LA01HU diluted at 1:800 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunofluorescence staining of HepG2 cells with CSB-PA013065LA01HU at 1:266, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) LPL Polyclonal antibody
Uniprot No.：

P06858
基因名：

LPL
別名：

EC 3.1.1 antibody; EC 3.1.1.34 antibody; HDLCQ11 antibody; LIPD antibody; LIPL_HUMAN antibody; Lipoprotein lipase antibody; LPL antibody; LPL protein antibody; MGC137861 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Lipoprotein lipase protein (162-246AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，LPL Antibody (CSB-PA013065LA01HU)，的標(biāo)記方式是Non-conjugated。對(duì)于LPL Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號(hào)	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA013065LB01HU	LPL Antibody, HRP conjugated	ELISA
FITC	CSB-PA013065LC01HU	LPL Antibody, FITC conjugated
Biotin	CSB-PA013065LD01HU	LPL Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:500-1:1000
IF	1:200-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity. Mediates margination of triglyceride-rich lipoprotein particles in capillaries. Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans.
基因功能參考文獻(xiàn)：
1. LPL-mediated release of essential fatty acid DHA regulates hematopoietic stem progenitor cell expansion and definitive hematopoiesis PMID: 29615667
2. the negatively charged IDR of GPIHBP1 traverses a vast space, facilitating capture of LPL by capillary endothelial cells and simultaneously contributing to GPIHBP1's ability to preserve LPL structure and activity. PMID: 29899144
3. nder optimal conditions, the electrochemical DNA biosensor exhibited desirable performance for the determination of rs1801177 (of the lipoprotein lipase )with a wide linearity ranging from 10 fM to 10nM and a relatively low detection limit of 3.33 fM (S/N=3). PMID: 29175215
4. A link between the expression of LPL in the tumor cells and a poor clinical outcome of patients suffering chronic lymphocytic leukemia has been established. (Review) PMID: 29206143
5. Pvu II restriction fragment length polymorphism associated with an elevated risk of hypertriglyceridemia [meta-analysis] PMID: 28502159
6. When her TG levels normalized after incidental use of prednisone, an autoimmune mechanism was suspected. Immunoblot analyses showed the presence of autoantibodies to LPL in the patient's plasma. Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy PMID: 28916403
7. Updated LPL structural models were generated by combining disulfide mapping, computational modeling, and data derived from single-molecule Forster resonance energy transfer. New computational suggest that LPL may dimerize using an interface that is different from the dimerization interface suggested by crystal packing contacts seen in structures of pancreatic lipase. PMID: 29303250
8. This meta-analysis suggested that LPL HindIII variants were associated with a decreased risk of stroke in the Asian population, but not in the non-Asian population. PMID: 28687421
9. LPL HindIII (+/-) and PvuII (+/-), but not the Ser447Ter, might significantly reduce the risk of ischemic stroke. PMID: 29718838
10. apoC-III potently inhibits triglyceride hydrolysis when LPL is bound to GPIHBP1 PMID: 28694296
11. The results of this meta-analysis suggested that the LPL S447X polymorphism is likely to be a protective factor in the development of hypertension. PMID: 28640651
12. Sequence variation in Kuwaiti Arabs was compared to other populations and was found to be similar with regards to the number of SNPs, InDels and distribution of the number of variants across the LPL gene locus and minor allele frequency PMID: 29438437
13. Regression analysis revealed significant risk for memory loss that are dependent on age and genetic variants like LPL. PMID: 28777751
14. The findings in this study suggest that there is a poor concordance between apo E genotyping and lipoprotein electrophoresis in diagnosing dysbetalipoproteinemia. PMID: 28689531
15. mutation of a conserved cysteine in GPIHBP1 abolishes the ability of GPIHBP1 to bind LPL PMID: 28476858
16. ANGPTL8 has a functional LPL inhibitory motif, but only inhibits LPL and increases plasma TG levels in mice in the presence of ANGPTL3 PMID: 28413163
17. The expression of COBLL1, LPL, and ZAP70 corresponded to patient prognosis and to IGHV mutational status, although not absolutely. When we combined all three markers together and performed the ROC analysis, AUC increased compared to the AUC of individual gene expression. PMID: 27185377
18. heterozygous N291S mutation in the lipoprotein lipase gene impairs whole-body insulin sensitivity and affects a distinct set of plasma metabolites in humans PMID: 28502509
19. The authors now show: (1) that ANGPTL4 inactivates LPL by catalyzing the unfolding of its hydrolase domain; (2) that binding to GPIHBP1 renders LPL largely refractory to this inhibition; and (3) that both the LU domain and the intrinsically disordered acidic domain of GPIHBP1 are required for this protective effect. PMID: 27929370
20. Carrier status for the two common LPL variants: 447Ter (low TG/high HDL-C) and 291Ser (high TG/low HDL-C) was determined. Compared with the reference variant, the prevalence of metabolic syndrome was lower in carriers of the 447Ter variant (11.2% vs. 17.9%, P < 0.001) but with no difference in carriers of the 291Ser variant (18.4% vs. 16.5%, P = 0.59). PMID: 27676127
21. A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease. Effects are unlikely to be solely predictable by the action of APOC3 through LPL. PMID: 27114411
22. LPL gene polymorphisms are not genetic markers for the development of stroke in the Colombian sample used. PMID: 28293042
23. Acute hypoxia strongly inhibits lipoprotein lipase activity in differentiated human preadipocytes. PMID: 27421877
24. novel mutations cause type 1 hyperlipoproteinemia by inducing a loss or reduction in LPL secretion accompanied by a loss of LPL enzymatic activity PMID: 27578112
25. LPL HindIII polymorphism was significantly associated with the risk of coronary artery disease (CAD); for Ser447X polymorphism, it was found that only XX genotype was significantly associated with CAD risk; PvuII polymorphism had no significant association with CAD risk; LPL HindIII polymorphism might serve as a potential biomarker for CAD risk PMID: 28275220
26. Rare variants in LPL and a common variant in APOA5 were more commonly found in Thai subjects with severe hypertriglyceridemia PMID: 27206937
27. apoC-I inhibited in situ LPL activity in adipocytes in both a concentration- and time-dependent manner. There was no change in postprandial WAT apoC-I secretion. WAT apoC-I secretion may inhibit WAT LPL activity and promote delayed chylomicron clearance in overweight and obese subjects PMID: 27040450
28. isothermal titration calorimetry (ITC) can be used for quantitative measurements of LPL activity and interactions under in vivo-like conditions, for comparisons of the properties of plasma samples from patients and control subjects as substrates for LPL, as well as for testing of drug candidates developed with the aim to affect the LPL system. PMID: 27845686
29. mAbs RE3 and RG3 bound with reduced affinity to a mutant GPIHBP1 containing an Ly6 domain mutation (W109S) that abolishes LPL binding. Immunohistochemistry studies with the GPIHBP1 mAbs revealed that human GPIHBP1 is expressed only in capillary endothelial cells. Finally, we created an ELISA that detects GPIHBP1 in human plasma. PMID: 27875259
30. Iotansulin decreased LPL mRNA levels in HepG2 cells and this was associated with phosphorylation of AKT and nuclear export of FOXA2. PMID: 28126606
31. The binding of both antibody 88B8 and GPIHBP1 to LPL depends on large segments of LPL's carboxyl-terminal domain. PMID: 27494936
32. Loss of Lipoprotein Lipase is associated with Pancreatitis. PMID: 27412455
33. In this study, most of the LPL gene variants were not significantly different in adolescents with normal and elevated triglceryide levels PMID: 28397436
34. The data suggest the importance of C-mannosylation for LPL functions. PMID: 28327359
35. The single nucleotide polymorphisms in lipoprotein lipase, ApoA5, and CETP were associated with serum triglycerides and HDL-cholesterol levels, but not with coronary artery disease in Pakistani population under study. PMID: 28143480
36. An LPL structural model suggests that the LPL S447X truncation exposes residues implicated in LPL binding to lipoprotein binding uptake receptors, such as GPIHBP1. PMID: 27984852
37. results confirm that LPL expression is a strong predictor of outcome in chronic lymphocytic leukemia, indicating a progressive course with poor survival PMID: 27757836
38. Reduced LPL expression in placenta, limited increase in LPL level in maternal plasma, and abnormal lipid profiles were found in patients with intrahepatic cholestasis of pregnancy. PMID: 27400425
39. The presence of rare damaging mutations in LPL was significantly associated with higher triglyceride levels and presence of coronary artery disease. PMID: 28267856
40. Data show that polymorphisms of rs662799 and rs2266788 in APOA5 gene, rs320 in LPL gene and rs708272 in CETP gene had significant association with the effect of the lipid-lowering therapy via atorvastatin on ischemic stroke patients. PMID: 27415775
41. NOTCH1 mutations are tightly associated with LPL gene expression. LPL expression is independently associated with poor outcome in CLL and can be measured as a categorical variable. PMID: 26558352
42. Polymorphisms in the LPL gene are associated with increased risk of acute non-biliary pancreatitis. PMID: 27270932
43. No significant increase of LPL activity was found at CM and VLDL overload after different kinds of food intake PMID: 27908779
44. LPL and PLTP appear to be novel glioma-associated proteins and play a role in the progression of human glioma PMID: 27864281
45. The acidic domain of GPIHBP1 stabilizes LPL catalytic activity by mitigating the global unfolding of LPL's catalytic domain. PMID: 26725083
46. Chronic lymphocytic leukemia patients with high UGT2B17 and LPL expression have significantly reduced survival. PMID: 26589911
47. Regulation of LPL by the miR-29, miR-1277 and miR-410 that is lost in presence of Hap4, a specific LPL TG-lowering haplotype. Consequently p.Ser474Ter association with TG concentration could be at least partially explained by its strong linkage disequilibrium with these functional 3'UTR SNPs. PMID: 26820803
48. eleterious mutations associated with LPL deficiency PMID: 27055971
49. In the present study, the D9N, N291S, and T495G polymorphisms of the LPL gene were not risk factors for the development of CVD. PMID: 26853140
50. S447X polymorphism is associated with postprandial triacylglycerol and glucose. PMID: 26999119
顯示更多

收起更多
相關(guān)疾病：

Lipoprotein lipase deficiency (LPL deficiency)
亞細(xì)胞定位：

Cell membrane; Peripheral membrane protein; Extracellular side. Secreted. Secreted, extracellular space, extracellular matrix.
蛋白家族：

AB hydrolase superfamily, Lipase family
組織特異性：

Detected in blood plasma. Detected in milk (at protein level).
數(shù)據(jù)庫(kù)鏈接：

HGNC: 6677

OMIM: 238600

KEGG: hsa:4023

STRING: 9606.ENSP00000309757

UniGene: Hs.180878

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human